

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

NCT06352281

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (8)

- Willingness to complete the informed consent process and to comply with study procedures and visit schedule;
- Men and women aged 8-75;
- Participants diagnosed with chronic (>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP;
- The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP;
- Platelet count <30 x 10⁹ / L;
- ... and 3 more (see full listing online)

Exclusion (18)

- All subjects with diseases which may cause secondary immune thrombocytopenia
- Patients with preventive splenectomy;
- Hemostatic disorders other than chronic thrombocytopenia;
- Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study;
- History of platelet agglutination abnormality that prevents reliable measurement of platelet counts;
- ... and 13 more (see full listing online)

Locations (1 total)

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, Yunnan, China